C4 Therapeutics, Inc.
CCCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -1.11 | -0.05 | -0.97 |
| FCF Yield | -26.16% | -38.70% | -38.65% | -5.95% |
| EV / EBITDA | -2.52 | -1.84 | -2.78 | -18.06 |
| Quality | ||||
| ROIC | -38.56% | -41.02% | -32.94% | -17.98% |
| Gross Margin | 100.00% | 62.72% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.62 | 0.81 | 0.83 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.60% | -23.18% | -2.15% | 3,577,356.87% |
| Free Cash Flow Growth | 39.81% | 2.59% | -26.28% | -29.96% |
| Safety | ||||
| Net Debt / EBITDA | -0.10 | 0.46 | -0.46 | 0.41 |
| Interest Coverage | 0.00 | -101.26 | -58.45 | -38.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 31.82 | 139.27 | 17.29 | 45.57 |